Tea Polyphenols as Natural Products for Potential Future Management of HIV Infection - an overview
DOI:
https://doi.org/10.18311/jnr/2016/4782Keywords:
AIDS, Catechin, HIV, Polyphenol, Phytomedicine, Tea, TheaflavinAbstract
Belonging to the Lentivirus genus of animal retroviruses, human immunodeficiency virus (HIV) is the etiological agent of acquired immunodeficiency syndrome (AIDS) which attacks cells of the immune system including CD4+ T lymphocytes, monocytes, macrophages and dendritic cells. A rapid progression to immunodeficiency and the higher transmissibility of HIV-1 compared to HIV-2 are hallmarks of the worldwide spread of AIDS. Conventional HIV treatments are limited by drug toxicity and by multi-drug resistance, caused by the high genetic variability of HIV. This has led researchers into new areas of drug discovery in search of novel therapeutic molecules. Accumulating evidence indicates that tea polyphenols possess a range of beneficial properties including anti-cancer, anti-inflammatory, anti-oxidative, neuro-protective, anti-bacterial, anti-fungal and anti-viral effects. The anti-HIV infection potential of tea polyphenols has been confirmed by several preclinical studies. This suggests that polyphenol-rich extracts of tea could be used as dietary supplements as part of a combined therapeutic regimen with conventional anti-HIV drugs. Phenolic structures may also be considered as backbones for the discovery of a new generation of anti-HIV remedies. This review provides a perspective on the anti-HIV activity of tea polyphenols and their development as a possible source of future drugs for the therapy of HIV/AIDS.Downloads
Metrics
Downloads
Published
How to Cite
Issue
Section
Accepted 2016-07-01
Published 2016-08-18
References
Ramana LN, Anand AR, Sethuraman S, Krishnan UM. Targeting strategies for delivery of anti-HIV drugs. J Control Release. 2014; 192:271–83.
Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011; 1:a006841.
Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH. The origins of acquired immunedeficiency syndrome viruses: where and when? Philos Trans R Soc Lond B Biol Sci. 2001; 356:867–76.
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014; 384:258–71.
Aldrich C, Hemelaar J. Global HIV–1 diversity surveillance. Trends Mol Med. 2012; 18:691–4.
Hemelaar J, Gouws E, Ghys PD, Osmanov S. WHO– UNAIDS Network for HIV Isolation and Characterization. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25:679–89.
Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and non-injection drug users. J Acquir Immune Defic Syndr. 2010; 55(S2):S84–7.
Donovan S. Pediatric HIV: current recommendations for diagnosis and treatment. Clin Microbiol Newsl. 2013; 35:127–31.
Duliege AM, Messiah A, Blanche S, Tardieu M, Griscelli C, Spira A. Natural history of human immunodeficiency virus type 1 infection in children: prognostic value of laboratory tests on the bimodal progression of the disease. Pediatr Infect Dis J. 1992; 11:630–5.
Reitz MS, Gallo RC. Human immunodeficiency virus. In: Mandell GL, Bennett JE, Dolin R (eds.) Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 2323–33.
Spira R, Lepage P, Msellati P, Van De Perre P, Leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda, Mother-to-Child HIV-1 Transmission Study Group. Pediatrics. 1999; 104:e56.
UNAIDS. AIDS by the numbers 2015. Geneva: 2015. Available from http://www.unaids.org/sites/default/ files/media_asset/AIDS_by_the_numbers_2015_en.pdf [Accessed on 13 May 2016].
Sabapathy K. Global roll-out of HIV treatment. Medicine. 2013; 41:479–82.
Kenya National Bureau of Statistics. Kenya Demographic and Health Survey, 2008-09. Calverton, Maryland: CBS & ICF Macro; 2010. Available from http://dhsprogram.com/ pubs/pdf/fr229/fr229.pdf [Accessed on 13 May 2016].
Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 20072010. HIV Surveillance Supplemental Report. 2012; 17(4). Available from http://www.cdc.gov/hiv/pdf/ statistics_hssr_vol_17_no_4.pdf [Accessed on 13 May 2016].
National Health and Family Planning Commission of the People's Republic of China. 2015 China AIDS Response Progress Report. Geneva: 2015. Available from http:// www.unaids.org/sites/default/files/country/documents/ CHN_narrative_report_2015.pdf [Accessed on 13 May 2016].
De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol. 2009; 19:287–99.
Narayan LC, Rai VR, Tewtrakul S. Emerging need to use phytopharmaceuticals in the treatment of HIV. J Pharm Res. 2013; 6:218–23.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. US Department of Health and Human Services, 2016. Available from https://aidsinfo.nih.gov/contentfiles/ lvguidelines/adultandadolescentgl.pdf [Accessed on 13 May 2016].
Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998; 279:1977–83.
Ferrazzano GF, Roberto L, Amato I, Cantile T, Sangianantoni G, Ingenito A. Antimicrobial properties of green tea extract against cariogenic microflora: an in vivo study. J Med Food 2011; 14:907–11.
Farzaei MH, Rahimi R, Abdollahi M. The role of dietary polyphenols in the management of inflammatory bowel disease. Curr Pharm Biotechnol. 2015; 16:196–210.
Sodagari HR, Farzaei MH, Bahramsoltani R, Abdolghaffari AH, Mahmoudi M, Rezaei N. Dietary anthocyanins as a complementary medicinal approach for management of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015; 9:807–20.
Farzaei MH, Farzaei F, Gooshe M, Abbasabadi Z, Rezaei N, Abdolghaffari AH. Potentially effective natural drugs in treatment for the most common rheumatic disorder: osteoarthritis. Rheumatol Int. 2015; 35:799–814.
Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr. 2005; 45:287–306.
Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci. 2007; 81:519–33.
UK Tea and Infusions Association. Tea Glossary and FAQ's. Available from https://www.tea.co.uk/tea-faqs [Accessed on 13 May 2016].28. Food and Agriculture Organization of the United Nations Statistics Division – Production. Rome: FAOSTAT, 2015. Available from http://faostat3.fao.org/browse/Q/QC/E [Accessed on 13 May 2016].
Wierzejska R. Tea and health – a review of the current state of knowledge. Przegl Epidemiol. 2014; 68:501–6, 595–9.
EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of health claims related to Camellia sinensis (L.) Kuntze (tea), including catechins in green tea and tannins in black tea, and protection of DNA, proteins and lipids from oxidative damage (ID 1103, 1276, 1311, 1708, 2664), reduction of acid production in dental plaque (ID 1105, 1111), maintenance of bone (ID 1109), decreasing potentially pathogenic intestinal microorganisms (ID 1116), maintenance of vision (ID 1280), maintenance of normal blood pressure (ID 1546) and maintenance of normal blood cholesterol concentrations (ID 1113, 1114) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010; 8:1463.
Otsuka T, Ogo T, Eto T, Asano Y, Suganuma M, Niho Y. Growth inhibition of leukemic cells by (−) epigallocatechin gallate, the main constituent of green tea. Life Sci. 1998; 63:1397–403.
Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res. 2005; 11:1918–27.
Shoji Y, Nakashima H. Glucose-lowering effect of powder formulation of African black tea extract in KK-A(y)/TaJcl diabetic mouse. Arch Pharm Res. 2006; 29:786–94.
Erba D, Riso P, Bordoni A, Foti P, Biagi PL, Testolin G. Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. J Nutr Biochem. 2005; 16:144–9.
Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Tea consumption and mortality after acute myocardial infarction. Circulation 2002; 105:2476– 81.
Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol. 2006; 545:51– 64.
Shimamura T, Zhao W-H, Hu Z-Q. Mechanism of action and potential for use of tea catechin as an antiinfective agent. Anti-Infect Agents Med Chem. 2007; 6:57–62.
Park BJ, Park J-C, Taguchi H, Fukushima K, Hyon S-H, Takatori K. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Biochem Biophys Res Commun. 2006; 347:401– 5.
Huang S-H, Tang YZ, Zhou X-M, Xie G, Kurihara H, He Z, et al. Study on anti-influenza virus effect of tea polyphenols in vitro and in vivo. Chaye Kexue. 2010; 30:302–8.
Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, et al. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta. 2005; 1723:270–81.
Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH, Dou QP. Recent advances on tea polyphenols. Front Biosci. 2012; 4:111–31.
Morel I, Lescoat G, Cogrel P, Sergent O, Pasdeloup N, Brissot P, et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on ironloaded rat hepatocyte cultures. Biochem Pharmacol. 1993; 45:13–19.
Kono K, Tatara I, Takeda S, Arakawa K, Hara Y. Antibacterial activity of epigallocatechin gallate against methicillinresistant Staphylococcus aureus. Kansenshogaku Zasshi. 1994; 68:1518–22.
Amarowicz R, Pegg RB, Bautista DA. Antibacterial activity of green tea polyphenols against Escherichia coli K12. Nahrung. 2000; 44:60–2.
Yang CS. Inhibition of carcinogenesis by tea. Nature. 1997; 389:134–5.
Farzaei MH, Abdollahi M, Rahimi R. Role of dietary polyphenols in the management of peptic ulcer. World J Gastroenterol. 2015; 21:6499–517.
Maeda-Yamamoto M, Kawahara H, Tahara N, Tsuji K, Hara Y, Isemura M. Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT1080 cells. J Agric Food Chem. 1999; 47:2350–4.
Nihal M, Ahmad N, Mukhtar H, Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer. 2005; 114:513–21.
Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr. 2003; 133:3275S–84S.
Kim S-H, Jun C-D, Suk K, Choi B-J, Lim H, Park S, et al. Gallic acid inhibits histamine release andpro-inflammatory cytokine production in mast cells. Toxicol Sci. 2006; 91:123–31.
Saleh F, Raghupathy R, Asfar S, Oteifa M, Al-Saleh N. Analysis of the effect of the active compound of green tea (EGCG) on the proliferation of peripheral blood mononuclear cells. BMC Complement Altern Med. 2014; 14:322.
Molina N, Bolin AP, Otton R. Green tea polyphenols change the profile of inflammatory cytokine release from lymphocytes of obese and lean rats and protect against oxidative damage. Int Immunopharmacol. 2015; 28:985– 96.
Marinovic MP, Morandi AC, Otton R. Green tea catechins alone or in combination alter functional parameters of human neutrophils via suppressing the activation of TLR-4/NFκB p65 signal pathway. Toxicol In Vitro. 2015; 29:1766–78.
Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol. 2003; 112:951–7.
Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A. Polyphenolic antioxidant (-)-epigallocatechin3-gallate from green tea as a candidate anti-HIV agent. AIDS 2002; 16:939–41.
Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2002; 53:19–34.
Haneda E, Furuya T, Asai S, Morikawa Y, Ohtsuki K. Biochemical characterization of casein kinase II as a protein kinase responsible for stimulation of HIV-1 protease in vitro. Biochem Biophys Res Commun. 2000; 275:434–9.
Tao P. The inhibitory effects of catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and DNA polymerases. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1992; 14:334–8.
Hartjen P, Frerk S, Hauber I, Matzat V, Thomssen A, Holstermann B, et al. Assessment of the range of the HIV1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG. AIDS Res Ther. 2012; 9:2.
Hauber I, Hohenberg H, Holstermann B, Hunstein W, Hauber J. The main green tea polyphenol epigallocatechin3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci USA 2009; 106:9033–8.
Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol. 2006; 118:1369–74.
Nance CL, Siwak EB, Shearer WT. Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy. J Allergy Clin Immunol. 2009; 123:459– 65.
Rrapo E, Zhu Y, Tian J, Hou H, Smith A, Fernandez F, et al. Green tea-EGCG reduces GFAP associated neuronal loss in HIV-1 Tat transgenic mice. Am J Transl Res. 2009; 1:72–9.
Giunta B, Obregon D, Hou H, Zeng J, Sun N, Nikolic V, et al. EGCG mitigates neurotoxicity mediated by HIV-1 proteins gp120 and Tat in the presence of IFN-γ: role of JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res. 2006; 1123:216–25.
Huang N, Yang L-M, Li X-L, Zheng C-B, Wang R-R, Yang Y-P, et al. Anti-HIV activities of extracts from Pu-erh tea. Chin J Nat Med. 2012; 10:347–52.
Kubota K, Sumi SH, Tojo H, Sumi-Inoue Y, I-chin H, Oi Y, et al. Improvements of mean body mass index and body weight in preobese and overweight Japanese adults with black Chinese tea (Pu-Erh) water extract. Nutr Res. 2011; 31:421–8.
Duh P-D, Yen G-C, Yen W-J, Wang B-S, Chang L-W. Effects of pu-erh tea on oxidative damage and nitric oxide scavenging. J Agric Food Chem. 2004; 52:8169–76.
Kuo K-L, Weng M-S, Chiang C-T, Tsai Y-J, Lin-Shiau S-Y, Lin J-K. Comparative studies on the hypolipidemic and growth suppressive effects of oolong, black, pu-erh, and green tea leaves in rats. J Agric Food Chem. 2005; 53:480– 9.
Way T-D, Lin H-Y, Kuo D-H, Tsai S-J, Shieh J-C, Wu JC, et al. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMPactivated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 2009; 57:5257–64.
Yang CS, Landau JM. Effects of tea consumption on nutrition and health. J Nutr. 2000; 130:2409–12.
Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr. 2003; 43:89–143.
Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr. 2003; 133:3262S–7S.
Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 2000; 71(S6):1698S–702S.
Hashimoto F, Kashiwada Y, Nonaka G, Nishioka I, Nohara T, Cosentino LM, et al. Evaluation of tea polyphenols as anti-HIV agents. Bioorg Med Chem Lett. 1996; 6:695– 700.
Yang J, Li L, Tan S, Jin H, Qiu J, Mao Q, et al. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection. Fitoterapia. 2012; 83:348–55.
Chattopadhyay C, Chakrabarti N, Chatterjee M, Mukherjee S, Sarkar K, Chaudhuri AR. Black tea (Camellia sinensis) decoction shows immunomodulatory properties on an experimental animal model and in human peripheral mononuclear cells. Pharmacognosy Res. 2012; 4:15–21.
World Health Organization. Global Health Observatory (GHO) data. Geneva: WHO; 2016. Available from http:// www.who.int/gho/hiv/en/ [Accessed on 13 May 2016].